7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Longitudinal Analysis of Patient Specific Predictors for Mortality in Sickle Cell Disease

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction

          White Blood Cell (WBC) count, %HbF, and serum creatinine (Cr), have been identified as markers for increased mortality in sickle cell anemia (SCA) but no studies have examined the significance of longitudinal rate of change in these or other biomarkers for SCA individuals.

          Methods

          Clinical, demographic and laboratory data from SCA patients seen in 2002 by our hospital system were obtained. Those who were still followed in 2012 (survival cohort) were compared to those who had died in the interim (mortality cohort). Patients lost to follow-up were excluded. Age adjusted multivariable Cox proportional hazards models were constructed to assess hazard ratios of mortality risk associated with the direction and degree of change for each variable.

          Results

          359 SCA patients were identified. Baseline higher levels of WBC, serum creatinine and hospital admissions were associated with increased mortality, as were alkaline phosphatase and aspartate aminotransaminase levels. Lower baseline levels of %HbF were also associated with increased mortality. When longitudinal rates of change for individuals were assessed, increases in Hb or WBC over patient baseline values were associated with greater mortality risk (HR 1.54, p = 0.02 and HR 1.16, p = 0.01 with negative predictive values of 87.8 and 94.4 respectively), while increasing ED use was associated with decreased mortality (HR 0.84, p = 0.01). We did not detect any increased mortality risk for longitudinal changes in annual clinic visits or admissions, creatinine or %HbF.

          Conclusions

          Although initial steady state observations can help predict survival in SCA, the longitudinal course of a patient may give additional prognostic information.

          Related collections

          Most cited references23

          • Record: found
          • Abstract: found
          • Article: not found

          Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes.

          Hemolysis, long discounted as a critical measure of sickle cell disease severity when compared with sickle vaso-occlusion, may be the proximate cause of some disease complications. New mechanistic information about hemolysis and its effects on nitric oxide (NO) biology and further examination of the subphenotypes of disease requires a reappraisal and deconstruction of the clinical features of sickle cell disease. The biology underlying clinical phenotypes linked to hemolysis may increase our understanding of the pathogenesis of other chronic hemolytic diseases while providing new insights into treating sickle cell disease. The pathophysiological roles of dysregulated NO homeostasis and sickle reticulocyte adherence have linked hemolysis and hemolytic rate to sickle vasculopathy. Nitric oxide binds soluble guanylate cyclase which converts GTP to cGMP, relaxing vascular smooth muscle and causing vasodilatation. When plasma hemoglobin liberated from intravascularly hemolyzed sickle erythrocytes consumes NO, the normal balance of vasoconstriction:vasodilation is skewed toward vasoconstriction. Pulmonary hypertension, priapism, leg ulceration and stroke, all subphenotypes of sickle cell disease, can be linked to the intensity of hemolysis. Hemolysis plays less of a role in the vaso-occlusive-viscosity complications of disease like the acute painful episode, osteonecrosis of bone and the acute chest syndrome. Agents that decrease hemolysis or restore NO bioavailability or responsiveness may have potential to reduce the incidence and severity of the hemolytic subphenotypes of sickle cell disease. Some of these drugs are now being studied in clinical trials.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Correction of sickle cell disease in transgenic mouse models by gene therapy.

            Sickle cell disease (SCD) is caused by a single point mutation in the human betaA globin gene that results in the formation of an abnormal hemoglobin [HbS (alpha2betaS2)]. We designed a betaA globin gene variant that prevents HbS polymerization and introduced it into a lentiviral vector we optimized for transfer to hematopoietic stem cells and gene expression in the adult red blood cell lineage. Long-term expression (up to 10 months) was achieved, without preselection, in all transplanted mice with erythroid-specific accumulation of the antisickling protein in up to 52% of total hemoglobin and 99% of circulating red blood cells. In two mouse SCD models, Berkeley and SAD, inhibition of red blood cell dehydration and sickling was achieved with correction of hematological parameters, splenomegaly, and prevention of the characteristic urine concentration defect.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Pulmonary complications of sickle cell disease.

                Bookmark

                Author and article information

                Contributors
                Role: Editor
                Journal
                PLoS One
                PLoS ONE
                plos
                plosone
                PLoS ONE
                Public Library of Science (San Francisco, CA USA )
                1932-6203
                20 October 2016
                2016
                : 11
                : 10
                : e0164743
                Affiliations
                [1 ]Department of Medical Oncology and Hematology, Yale New Haven Medical Center, New Haven, CT, 06510, United States of America
                [2 ]Division of Hematology, Department of Medicine and Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, 10467, United States of America
                [3 ]Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, 10467, United States of America
                Morehouse School of Medicine, UNITED STATES
                Author notes

                Competing Interests: The authors have declared that no competing interests exist.

                • Conceptualization: SAC HHB.

                • Data curation: SAC HHB ZE ND.

                • Formal analysis: SAC HHB HWC.

                • Funding acquisition: HHB.

                • Investigation: SAC HHB ND ZE.

                • Methodology: SAC HHB HWC.

                • Supervision: HHB.

                • Visualization: SAC HHB.

                • Writing – original draft: SAC HHB.

                • Writing – review & editing: SAC HHB.

                ‡ These authors also contributed equally to this work.

                Article
                PONE-D-16-30281
                10.1371/journal.pone.0164743
                5072581
                27764159
                3e3a2adb-a741-4624-b0f9-7293254d49b9
                © 2016 Curtis et al

                This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

                History
                : 28 July 2016
                : 29 September 2016
                Page count
                Figures: 1, Tables: 4, Pages: 11
                Funding
                Funded by: NCRR
                Award ID: UL1 RR025750
                Award Recipient :
                Funded by: NCRR
                Award ID: KL2 RR025749
                Award Recipient :
                Funded by: NCRR
                Award ID: TL1 RR025748
                Award Recipient :
                This publication was supported in part by the CTSA Grant UL1 RR025750, KL2 RR025749 and TL1 RR025748 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessary represent the official view of the NCRR or NIH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
                Categories
                Research Article
                People and Places
                Demography
                Death Rates
                Biology and Life Sciences
                Population Biology
                Population Metrics
                Death Rates
                Medicine and Health Sciences
                Clinical Genetics
                Genetic Diseases
                Autosomal Recessive Diseases
                Sickle Cell Disease
                Medicine and Health Sciences
                Hematology
                Hemoglobinopathies
                Sickle Cell Disease
                Medicine and Health Sciences
                Critical Care and Emergency Medicine
                Biology and Life Sciences
                Biochemistry
                Proteins
                Hemoglobin
                Biology and Life Sciences
                Biochemistry
                Biomarkers
                Creatinine
                Medicine and Health Sciences
                Health Care
                Health Care Facilities
                Hospitals
                Biology and Life Sciences
                Biochemistry
                Enzymology
                Enzymes
                Phosphatases
                Biology and Life Sciences
                Biochemistry
                Proteins
                Enzymes
                Phosphatases
                Biology and Life Sciences
                Cell Biology
                Cellular Types
                Animal Cells
                Bone Marrow Cells
                Reticulocytes
                Biology and Life Sciences
                Cell Biology
                Cellular Types
                Animal Cells
                Blood Cells
                Red Blood Cells
                Reticulocytes
                Custom metadata
                Due to restrictions concerning patient privacy, data are available upon request. Requests for the data may be sent to the corresponding author.

                Uncategorized
                Uncategorized

                Comments

                Comment on this article